Key result
RAAS inhibitors for tetralogy of Fallot offer mechanistic insight to guide future RV failure therapies.
Why the study?
Do Renin-Angiotensin-Aldosterone System Inhibitors improve outcomes in patients with Right Ventricular Dysfunction in Tetralogy of Fallot?
Do Renin-Angiotensin-Aldosterone System Inhibitors improve outcomes in patients with Right Ventricular Dysfunction in Tetralogy of Fallot?
The paper discusses mechanisms of RV failure and the potential for developing RV-specific heart failure therapies in Tetralogy of Fallot.
mechanisms of RV failure.These studies may pave the way toward developing RV-specific heart failure therapies and designing future clinical trials.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2018) studied this question. Renin-angiotensin-aldosterone system inhibitors for right ventricular dysfunction in tetralogy of Fallot may help elucidate mechanisms of RV failure and guide future RV-specific therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: